EX-10.29 33 ff12018ex10-29_aptorum.htm ADDENDUM TO LICENSE AGREEMENT FOR NLS-1 DATED FEBRUARY 9, 2018

Exhibit 10.29

ADDENDUM TO LICENSE AGREEMENT

This Addendum, effective as of 9 February 2018, is hereby made a part of the License Agreement entered into as of 3 July 2017 (“Agreement”) between Aptorum Therapeutics Limited (formerly known as APTUS Therapeutics Limited), hereinafter “Aptorum” on the one part and

| (1) | PolyU Technology and Consultancy Co. Ltd. (“PTeC”),

| (2) | The Royal Institution for the Advancement of Learning/McGill University (“McGill”),

| (3) | Wayne State University (“WSU”),

| (4) | H. Lee Moffitt Cancer Center and Research Institute Inc. (“MCC”) and

| (5) | The Chinese University of Hong Kong (“CUHK”)

are hereinafter referred to collectively as the “Licensors”.

WHEREAS, the Parties have entered into a License Agreement dated 3 July 2017 whereby Licensors have licensed certain patent rights to APTUS Therapeutics Limited as set out in the Agreement:

WHEREAS, APTUS Therapeutics Limited changed its company name to Aptorum Therapeutics Limited effective from 19 September 2017;

WHEREAS, the company name change will have no impact on the Agreement and Aptorum will continue to perform all of its obligations under the Agreement;

WHEREAS, it is in the mutual best interests of Aptorum and Licensors to amend the Agreement to reflect this company name change; and

WHEREAS, all parties agree to amend said Agreement. NOW, THEREFORE, the parties hereto agree as follows:

| 1) | Effective as of 19 September 2017 APTUS Therapeutics Limited changed its legal company name to Aptorum Therapeutics Limited.

| 2) | Aptorum will continue to perform all of its duties, responsibilities, and obligations under the Agreement.

| 3) | Licensors hereby consent to continuing the Agreement with Aptorum.

| 4) | Where the term APTUS Therapeutics Limited shall appear in the original Agreement as amended, the term shall hereinafter mean and refer to Aptorum Therapeutics Limited.

| 5) | Except as expressly amended hereby, all the remaining provisions of the Agreement shall remain in full force and effect.

| 1 |

In Witness whereof the parties hereto have signed this Agreement on the date first above written.

SIGNED for and on behalf of

PolyU Technology and Consultancy Co. Ltd. |
/s/ Miranda Lou |
Signature |
Dr. Miranda Lou |
Printed Name |
Director |
Title |
12 JAN 2018 |
Date |

[The remainder of this page is intentionally left blank.]

| 2 |

In Witness whereof the parties hereto have signed this Agreement on the date first above written.

SIGNED for and on behalf of

The Royal Institution for the Advancement of Learning/McGill University

/s/ Martha Crago |
Signature |
Prof. Martha Crago |
Printed Name |
Vice-Principal Research & Innovation |
Title |
11/14/17 |
Date |

[The remainder of this page is intentionally left blank.]

| 3 |

In Witness whereof the parties hereto have signed this Agreement on the date first above written.

SIGNED for and on behalf of

Wayne State University

/s/ Joan Dunbar |
Signature |
Joan Dunbar, PhD |
Printed Name |
Associate Vice President Technology Committee |
Title |
Nov 3, 2017 |
Date |

[The remainder of this page is intentionally left blank.]

| 4 |

In Witness whereof the parties hereto have signed this Agreement on the date first above written.

SIGNED for and on behalf of

H. Lee Moffitt Cancer Center and Research Institute Inc.

/s/ James K. Mule |
Signature |
James J. Mule, PhD |
Printed Name |
Associate Center Director, Translational Science |
Title |
11/6/17 |
Date |

[The remainder of this page is intentionally left blank.]

| 5 |

In Witness whereof the parties hereto have signed this Agreement on the date first above written.

SIGNED for and on behalf of

The Chinese University of Hong Kong

/s/ Walter K.K. Ho |
Signature |
Walter K.K. Ho (Prof) |
Printed Name |
Director |
Title |
03 JAN 2018 |
Date |

[The remainder of this page is intentionally left blank.]

| 6 |